Docetaxel and Epirubicin as First-Line Treatment for Patients with Metastatic Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial

REFERENCES

• Valero V., Holmes F. A., Walters R. S., Theriault R. L., Esparza L., et al. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J. Clin. Oncol. 1995; 13: 2886–2894, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chevallier B., Fumoleau P., Kerbrat P., Dieras V., Roche H., et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A Phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 1995; 13: 314–322, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chan S., Friedrichs K., Noel D., Pinter T., Van Belle S., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 1999; 17: 2341–2354, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gianni L., Munzone E., Capri G., Fulfaro F., Tarenzi E., et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol. 1995; 13: 2686–2699, [CSA]
   Google Scholar
• Miller K. D., McCaskill-Stevens W., Sisk J., Loesch D. M., Monaco F., Seshadri R., Sledge G. W., Jr. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of The Hoosier Oncology Group. J. Clin. Oncol. 1999; 17: 3033–3037, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Luck H. J., Thomssen C., Dubois A., Untch M., Lisboa B., Kohler G., Diergarten K. Metastatic breast cancer: Experience with combination paclitaxel plus epirubicin. Oncology 1998; 12(1)36–39, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Alba E., Martin M., Ramos M., Adrover E., Balil A., , Sanchez-Rovira P., Amenedo M., Casado A., Spanish Breast Cancer Research Group, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J. Clin. Oncol. 2004; 22: 2587–2593, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bria E., Giannerelli D., Felici A., Peters W. P., Nistico C., et al. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Pooled analysis of 2805 patients. Cancer 2005; 103: 672–679, [CSA]
   Google Scholar
• Perez D. J., Harvey V. J., Robinson B. A., Atkinson C. H., et al. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J. Clin. Oncol. 1991; 9: 2148–2152, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jain K. K., Casper E. S., Geller N. L., Hakes T. B., Kaufman R. J., et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J. Clin. Oncol. 1985; 3: 818–826, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Italian Multicentre Breast Study With Epirubicin: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. J. Clin. Oncol. 1988; 6: 976–982, [CSA]
   PubMed Web of Science ®Google Scholar
• French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J. Clin. Oncol. 1988; 6: 679–688, [CSA]
   PubMed Web of Science ®Google Scholar
• Eidtmann H., Astner A., Ernhardt B., Borquez D., Raab G., et al. Phase II study of docetaxel and epirubicin as first-line chemotherapy in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 114a, [CSA]
   Google Scholar
• Estevez L. G., Domine M., Martin I., Casado V., Robles L., Leon A., Lobo F. Docetaxel in combination with epirubicin as treatment of metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 119a, [CSA]
   Google Scholar
• Steger G. G., Wenzel C., Schmidinger M. P., Locker G. J., Samonigg H., et al. Phase I trial of weekly epirubicin/docetaxel (WED) in the neoadjuvant treatment of operable breast cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 94a, [CSA]
   Google Scholar
• Kaplan E. L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 457–481, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Luck H., Thomssen C., Untch M., Kuhn W., Eidtmann H., et al. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc. Am. Soc. Clin. Oncol. 2000; 19: 73a, [CSA]
   Google Scholar
• Jassem J., Pienkowski T., Pluzanska A., Jelic S., Gorbunova V., , Central & Eastern Europe and Israel Paclitaxel Breast Cancer Study Group, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J. Clin. Oncol. 2001; 19: 1707–1715, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Carmichael J. UKCCCR trial of epirubicin and cyclophosfamide (EC) vs epirubicin and Taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 2001; 20: 22a, [CSA]
   Google Scholar
• Mackey J. R., Paterson A., Dirix L. Y., Dewar J., Chap L., et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first-line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 2002; 21: 35a, [CSA]
   Google Scholar
• Biganzoli L., Cufer T., Bruning P., Coleman R., Duchateau L., et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first line chemotherapy in metastatic breast cancer: EORTC 10961. J. Clin. Oncol. 2002; 20: 3114–3121, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nabholtz J. M., Falkson C., Campos D., Szanto J., Martin M., , TAX 306 Study Group, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J. Clin. Oncol. 2003; 21: 968–975, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bontenbal M., Braun J. J., Creemers G. J. Phase III study comparing AT (Adriamycin, docetaxel) to FAC (flourouracil, Adriamycin, cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). Proc. Eur. Cancer. Conf. 2003; 5201
   Google Scholar
• Sledge G. W., Neuberg D., Bernardo P., Ingle J. N., Martino S., Rowinsky E. K., Wood W. C. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J. Clin. Oncol. 2003; 21: 588–592, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar